Suppr超能文献

来自加纳阿克拉未接受过治疗患者的1型人类免疫缺陷病毒聚合酶基因的变异性

Variability of the human immunodeficiency virus type 1 polymerase gene from treatment naïve patients in Accra, Ghana.

作者信息

Sagoe Kwamena William Coleman, Dwidar Magdar, Lartey Margaret, Boamah Isaac, Agyei Afrakoma Adjoa, Hayford Anna Aba, Mingle Julius Abraham Addo, Arens Max Q

机构信息

Clinical Virology Laboratory (Department of Microbiology), University of Ghana Medical School, Accra, Ghana.

出版信息

J Clin Virol. 2007 Oct;40(2):163-7. doi: 10.1016/j.jcv.2007.07.016. Epub 2007 Sep 10.

Abstract

BACKGROUND

Little is known about the HIV-1 drug resistance mutations in Ghana.

OBJECTIVES

To determine the background protease (PR) and reverse transcriptase (RT) mutations of HIV-1 from treatment naïve patients in Ghana.

STUDY DESIGN

Twenty-five plasma samples randomly selected were analyzed for drug resistance mutations. The molecular phylogeny and recombinant patterns of the polymerase gene of HIV-1 were also analysed.

RESULTS

No major drug-resistance mutations were seen in protease or reverse transcriptase genes. The L10I, L10V, V11I and E35G minor mutations were seen in four patients, while the V179E was observed in a patient with subtype G. An insertion of lysine was found at codon 36 of the protease gene of one patient. The predominant subtype was the CRF02_AG strain (n=22), but 3 (13.6%) of these were recombinants with HIV-1 subtype K and/or A1. Two patients harboured unclassified/complex strains with D/CRF01_AE and G/CRFAG_02 subtypes for the PR and RT, respectively, using the Stanford Database. Viral loads (VL) ranged from 2290 to >1,500,000c/ml (mean=339,065c/ml).

CONCLUSIONS

Treatment naïve patients in Ghana before scale-up may have minor but not major PR mutations and high viral loads. The clinical effects of minor mutations/polymorphisms in the PR and RT genes and recombinants need to be investigated.

摘要

背景

关于加纳的HIV-1耐药性突变情况知之甚少。

目的

确定加纳未接受过治疗的患者中HIV-1的蛋白酶(PR)和逆转录酶(RT)背景突变。

研究设计

对随机选取的25份血浆样本进行耐药性突变分析。同时分析HIV-1聚合酶基因的分子系统发育和重组模式。

结果

蛋白酶或逆转录酶基因中未发现主要耐药性突变。4名患者出现了L10I、L10V、V11I和E35G等次要突变,1名G亚型患者出现了V179E突变。在1名患者的蛋白酶基因第36密码子处发现赖氨酸插入。主要亚型为CRF02_AG毒株(n = 22),但其中3株(13.6%)为与HIV-1 K亚型和/或A1亚型的重组体。使用斯坦福数据库,2名患者分别携带PR和RT的未分类/复杂毒株,PR为D/CRF01_AE亚型,RT为G/CRFAG_02亚型。病毒载量(VL)范围为2290至>1,500,000拷贝/毫升(平均 = 339,065拷贝/毫升)。

结论

在扩大治疗规模之前,加纳未接受过治疗的患者可能存在次要而非主要的PR突变且病毒载量较高。PR和RT基因中的次要突变/多态性以及重组体的临床影响需要进一步研究。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验